Company profile for Glycomine

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat pho...
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
733 Industrial Rd, San Carlos, California 94070
Telephone
Telephone
(650) 401-2016
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-09-03/glycomine-initiates-dosing-in-a-global-randomized-placebo-controlled-phase-2b-study-of-glm101-for

PHARMAWEB
03 Sep 2025

https://www.businesswire.com/news/home/20250416688920/en/Glycomine-Announces-%24115-Million-Series-C-Financing-to-Advance-Lead-Drug-Candidate-GLM101-into-a-Phase-2b-Clinical-Trial-for-PMM2-CDG

BUSINESSWIRE
16 Apr 2025

https://www.businesswire.com/news/home/20241008340338/en

BUSINESSWIRE
10 Oct 2024

https://www.businesswire.com/news/home/20240918280418/en

BUSINESSWIRE
18 Sep 2024

https://www.businesswire.com/news/home/20240304707699/en

BUSINESSWIRE
04 Mar 2024

https://www.businesswire.com/news/home/20231211003939/en

BUSINESSWIRE
11 Dec 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty